Sirtex wants medical professionals and patients to understand how SIR-Spheres® Y-90 resin microspheres can help improve clinical outcomes and the quality of life for people with liver cancer. To help achieve this objective, we want to provide medical journalists and health writers with balanced and comprehensive information about our company, our technology and the medical needs we address.
11 Oct 2021
Sirtex Medical and China Grand Pharmaceutical announce successful first administration of SIR-Spheres® Y-90 resin microspheres in China
08 Jun 2021
Sirtex Medical provides donations to Massachusetts Institute of Technology (MIT) and Brigham and Women’s Hospital in support of the Artzi Lab, as part of Sirtex’s corporate citizenship strategy to support research and innovation.
10 May 2021
DOORwaY-90 study for SIR-Spheres® therapy as first-line treatment for hepatocellular carcinoma enrolls first patient
Now leaving sirtex.com
You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.
Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.
Click 'Continue' to proceed to the third-party Web site.
Now leaving sirtex.com
You are about to leave the Sirtex Website. This link is provided to you as a service and will take you to the Sirtex Virtual Booth.
Sirtex is responsible for the content of the Virtual Booth, which is hosted on a website maintained by a third-party. Except for Sirtex’s Virtual Booth experience, please be aware that Sirtex takes
no responsibility for the other content of these external sites, nor do we endorse, warrant, or guarantee the products, services or information described or offered on other internet sites.
You are now leaving your current sirtex.com region
The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region.
Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.
Click 'Continue' to proceed to the other Sirtex region Web site.
Effective May 7, 2021, SIR-Spheres will have the following indication for use:
SIR-Spheres Y-90 resin microspheres are indicated for the treatment of unresectable hepatocellular carcinoma (HCC) and
unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy.
Click here to view our Technical Bulletin.